Pricing Log in Create free account
Friday 6 November 2026 Export MYO’s income statement to Excel — free account

Myomo, Inc.

MYO Healthcare Medical Devices

Myomo, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.9 million, up 25.7% from fiscal 2024.

Revenue
+21.3%
EPS
+18.2%
Free cash flow
+80.0%
Total debt
+199.5%

Quarter to June 2026, against a year earlier

1.21 0.02 +1.68%
Market cap
$47.1M
P/E
0.0×
Fwd P/E
−4.0×
Dividend yield
—
F-score
2/9
Altman Z
−3.04
Beneish M
−2.81
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.43
Sold, $m 0.21
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 3 — 3 1 — — — — —
Sell — — — — — 2 — — 2 2 — —
Insider Ownership 16.93%

Capital & Financial Ratios $m

Size
Market Cap 47.13
Revenue ttm 43.26
Net income ttm (14.51)
Free cash flow ttm (9.09)
Net debt Q (1.47)
Valuation
P/E 0.00
Forward P/E (3.95) (negative: loss-making)
Price / sales 1.17
Forward P/S Powerpack
Price / FCF 0.00
Price / book 8.72 (above 6: high)
Financial health
Current ratio Q 2.31 (at or above 1.5: strong)
Debt / equity Q 2.06 (above 2: weak)
Interest coverage Q (6.26)
Growth
Revenue growth Q +21.26% (above 0%: growing)
Operating income growth Q +50.89% (above 0%: growing)
EPS, this year +15.14% (at or above 15%: strong)
EPS, next year A +24.20% (at or above 15%: strong)
Revenue, next year A +11.42% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +21.35% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.1×, against a ten-year median of 2.2×; over the ten years it ranged from −1.3× in 2020 to 20.7× in 2018.
P/S against its own 10 years 24.33%
10-year low 10-year high
P/B against its own 10 years 81.75%
10-year low 10-year high
EV/Sales against its own 10 years 31.15%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 25 18 13
Receivables 2 4 4 5
Inventory 2 3 3 3
Other — — — —
14 33 28 25
2023 2024 2025 Q'26
Payables 5 9 6 8
ST’ Debt — — — 0
Other — — 1 1
5 10 8 11

Compound Annual Growth %

10y 5y 3y
Sales 50.43% 40.10% 38.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (0.28%) 21.49%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.10 Actual −0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.11 −0.09 Beat by 0.02
Q4 FY25 −0.09 −0.08 Beat by 0.01
Q1 FY26 −0.12 −0.09 Beat by 0.03
Q2 FY26 −0.10 −0.07 Beat by 0.03
Q3 FY26 −0.08 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.07) (0.09) — — —
’25 (0.08) (0.11) (0.09) (0.09) (0.37)
’24 (0.10) (0.03) (0.03) (0.01) (0.16)
’23 (0.11) (0.04) (0.06) (0.07) (0.28)
’22 (0.41) (0.42) (0.40) (0.29) (1.52)
’21 (0.57) (0.46) (0.36) (0.52) (1.89)
’20 (2.51) (1.12) (0.70) (0.37) (3.67)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 10 12 — — —
’25 10 10 10 11 41
’24 4 8 9 12 33
’23 3 6 5 5 19
’22 4 4 4 4 16
’21 2 3 4 4 14
’20 1 1 2 4 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (3) (9) (2) (1) (15)
’24 (3) (2) (1) 3 (3)
’23 (2) 0 (2) (2) (6)
’22 (2) (3) (3) (2) (10)
’21 (2) (3) (2) (2) (10)
’20 (2) (4) (2) (1) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (3) (10) (3) (1) (18)
’24 (3) (2) (2) 3 (5)
’23 (2) 0 (2) (2) (6)
’22 (2) (3) (3) (2) (10)
’21 (2) (4) (2) (2) (10)
’20 (2) (4) (2) (1) (9)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 2 2 4 8 14 16 19 33 41 43 +49.4% 46 51 64 +16.1%
Gross margin, % 74.42 67.59 70.20 62.98 65.71 74.42 65.91 68.51 71.23 65.70 68.35 (8.7) pt
EBT (4) (12) (10) (11) (12) (10) (11) (8) (6) (15) (14) +17.2%
EBT margin, % (327.83) (776.03) (422.11) (279.15) (152.49) (74.21) (68.47) (41.53) (17.87) (36.82) (32.52) +291.0 pt
Net income (4) (12) (10) (11) (12) (10) (11) (8) (6) (16) (15) +17.6%
Per share, $
Per share, $ Revenue 31.20 10.84 5.96 6.93 2.28 2.38 2.21 0.65 0.86 0.98 1.01 (31.9%)
Earnings (123.97) (87.99) (25.22) (19.35) (3.67) (1.89) (1.52) (0.28) (0.16) (0.37) (0.34) (47.6%)
Cash flow (90.57) (42.79) (23.43) (18.67) (2.71) (1.64) (1.45) (0.21) (0.09) (0.35) (0.17) (46.1%)
Capex (0.05) (0.47) (0.31) (0.09) (0.01) (0.06) (0.02) 0.00 (0.04) (0.08) (0.05) +4.5%
Free cash flow (90.62) (43.26) (23.74) (18.76) (2.73) (1.69) (1.47) (0.21) (0.12) (0.43) (0.21) (44.9%)
Book value (137.38) 86.55 15.67 3.29 3.47 2.64 0.90 0.30 0.65 0.27 0.14 n/m
Shares, m 0 0 0 1 3 6 7 29 38 42 42 +119.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 10.10 7.25 1.30 2.96 2.88 0.24 7.34 7.47 0.93 1.17 4.0
P/B 0.00 1.27 2.76 2.74 1.94 2.59 0.58 15.72 9.84 3.34 8.72 4.1
EV/Sales 0.00 2.62 5.10 0.83 1.36 1.81 (0.07) 6.92 6.73 0.79 1.14 2.6
EV/FCF (2.01) (0.66) (1.28) (0.31) (1.14) (2.55) 0.11 (21.07) (47.10) (1.82) (5.43) (7.8)
Cash, $m
Cash, $m Operating cash flow (3) (6) (10) (10) (9) (10) (10) (6) (3) (15) (7) +18.3%
Capex 0 0 0 0 0 0 0 0 (1) (3) (2) +129.3%
Free cash flow (3) (6) (10) (10) (9) (10) (10) (6) (5) (18) (9) +21.0%
Balance, $m
Balance, $m Working capital (2) 12 6 2 12 15 6 8 23 19 14 n/m
Net debt 3 (13) (7) (2) (12) (15) (5) (9) (25) (7) (1) n/m
Shareholders’ equity (5) 12 6 2 12 15 6 9 25 11 6 n/m
Returns, %
Returns, % ROA (276.84) (161.95) (92.71) (154.71) (114.83) (63.28) (70.87) (65.86) (21.76) (38.51) (39.20) +238.3 pt
ROIC 0.00 0.00 0.00 (55,759.30) 0.00 (2,241.55) (549.61) (4,169.11) 0.00 (212.70) (167.90) (212.7) pt
ROE 27.90 497.94 (109.34) (279.03) (182.74) (81.65) (98.50) (106.17) (36.69) (86.24) (123.76) (114.1) pt
People
People Employees 23 24 46 50 64 93 106 106 185 195 — +26.8%
Revenue/emp, $m 0.05 0.06 0.05 0.08 0.12 0.15 0.15 0.18 0.18 0.21 — +17.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Myomo, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LNSR LENSAR, Inc. $67.6M 3.9× 6.9× +18.37% (above 0%: growing) n/m +96.81% (above 0%: growing) 59.27% 12.94% Compare
COCH Envoy Medical, Inc. $55.0M — (loss-making) — (loss-making) +57.14% (above 0%: growing) n/m −22.44% (below 0%: shrinking) (269.70%) (8,389.39%) Compare
SRTS Sensus Healthcare, Inc. $48.1M — (loss-making) — (loss-making) −68.69% (below 0%: shrinking) n/m −201.65% (below 0%: shrinking) 33.58% (138.86%) Compare
MYO Myomo, Inc. $47.1M — (loss-making) — (loss-making) +21.26% (above 0%: growing) n/m +80.02% (above 0%: growing) 72.13% (19.26%)
MDAI Spectral AI, Inc. $44.4M — (loss-making) — (loss-making) −30.42% (below 0%: shrinking) n/m −21.86% (below 0%: shrinking) 31.58% (122.70%) Compare
XTNT Xtant Medical Holdings, Inc. $42.1M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
CVRX CVRx, Inc. $39.2M — (loss-making) — (loss-making) −5.84% (below 0%: shrinking) n/m −9.91% (below 0%: shrinking) 86.74% (94.31%) Compare
TELA TELA Bio, Inc. $35.2M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%) Compare
SNWV Sanuwave Health Inc. $19.4M 1.3× — (loss-making) −3.13% (below 0%: shrinking) n/m +86.75% (above 0%: growing) 76.23% (2.88%) Compare
Median of peers $43.3M — — −5.16% — −19.79% 58.58% (71.22%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 14 May 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.20m (348.55k) 178.08
2024 1.24m 1.51m 1,259.29
2023 663.90k 2.12m 979.66

Ownership

Directors and executive officers, together 12.14%
Rosalind Advisors, Inc. 9.99%
Joseph M. Manko Jr. 5.46%
Horton Capital Partners, L.P. 5.46%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Myomo, Inc. (MYO) Latest News

12 Oct

Impact 4 · · Business Wire

9 Aug

Impact 3 · · MarketBeat

6 Aug

Impact 4 ·

5 Aug

Impact 3 ·

7 May

Impact 4 · · Moby
Impact 4 · · Business Wire
Impact 4 · · Business Wire earnings
Impact 3 · · Zacks
Impact 3 ·

4 May

Impact 4 · · Business Wire

20 Apr

Impact 4 ·

12 Mar

Impact 4 · · Simply Wall St.

11 Mar

Impact 4 ·
Impact 4 · · Thomson Reuters StreetEvents transcript
Impact 4 · · GuruFocus.com

9 Mar

Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · Zacks

11 Nov

Impact 4 · · GuruFocus.com transcript

10 Nov

Impact 3 · · Zacks
Impact 3 · · Business WireMotley FoolMotley FoolGuruFocus.comGuruFocus.comStockStoryGuruFocus.comMotley Fool

2 Sep

Impact 3 ·

12 Aug

Impact 4 · · GuruFocus.com

11 Aug

Impact 3 ·
Impact 3 ·

10 Jul

Impact 4 · · Insider Monkey

18 Jun

Impact 4 · · Business Wire

8 May

Impact 4 · · GuruFocus.com

1 May

Impact 4 · · Business Wire

30 Apr

Impact 4 · · Business Wire
stockrow.com/MYO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com